• Consensus Rating: Buy
  • Consensus Price Target: $228.90
  • Forecasted Upside: 20.73 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$189.60
▼ -2.22 (-1.16%)

This chart shows the closing price for PEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Penumbra Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PEN

Analyst Price Target is $228.90
▲ +20.73% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Penumbra in the last 3 months. The average price target is $228.90, with a high forecast of $300.00 and a low forecast of $163.00. The average price target represents a 20.73% upside from the last price of $189.60.

This chart shows the closing price for PEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Penumbra. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/7/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/5/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/3/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/3/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/2/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/16/2022BTIG ResearchReiterated RatingBuy$213.00 ➝ $239.00Low
9/13/2022Truist FinancialBoost TargetBuy$180.00 ➝ $230.00Low
9/9/2022Needham & Company LLCUpgradeHold ➝ Buy$244.00Low
8/5/2022Canaccord Genuity GroupLower TargetBuy$244.00 ➝ $189.00Low
7/22/2022Truist FinancialLower Target$180.00Low
7/21/2022Deutsche Bank AktiengesellschaftLower Target$250.00 ➝ $163.00Low
7/18/2022BTIG ResearchLower TargetBuy$272.00 ➝ $213.00Low
7/18/2022Royal Bank of CanadaInitiated CoverageOutperform$195.00Low
5/17/2022CitigroupLower Target$280.00 ➝ $220.00N/A
5/4/2022Wells Fargo & CompanyLower Target$321.00 ➝ $265.00High
5/3/2022William BlairReiterated RatingOutperformHigh
4/19/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$250.00High
3/18/2022BTIG ResearchInitiated CoverageBuy$272.00Medium
3/8/2022Needham & Company LLCInitiated CoverageHoldHigh
2/23/2022Truist FinancialLower Target$350.00 ➝ $300.00High
2/23/2022Canaccord Genuity GroupLower Target$335.00 ➝ $244.00High
2/23/2022JPMorgan Chase & Co.Lower TargetOverweight$325.00 ➝ $300.00High
2/23/2022CitigroupLower TargetBuy$300.00 ➝ $280.00High
2/8/2022BTIG ResearchReiterated RatingBuy$272.00Low
9/16/2021Truist FinancialInitiated CoverageBuy$350.00Low
9/15/2021Truist FinancialInitiated CoverageBuy$350.00Low
8/10/2021CitigroupBoost TargetBuy$335.00 ➝ $340.00High
8/10/2021BTIG ResearchBoost TargetBuy$299.00 ➝ $308.00High
6/8/2021Wells Fargo & CompanyReiterated RatingBuyMedium
6/4/2021BTIG ResearchUpgradeNeutral ➝ Buy$291.00High
5/5/2021CitigroupBoost Target$325.00 ➝ $335.00High
5/5/2021Wells Fargo & CompanyBoost TargetOverweight$310.00 ➝ $321.00High
2/24/2021CitigroupBoost TargetBuy$255.00 ➝ $325.00Low
2/24/2021Wells Fargo & CompanyBoost TargetOverweight$260.00 ➝ $310.00Low
12/16/2020Wells Fargo & CompanyLower TargetOverweight$265.00 ➝ $215.00Medium
12/16/2020BTIG ResearchDowngradeBuy ➝ NeutralN/A
10/29/2020Smith Barney CitigroupBoost Target$264.00 ➝ $270.00Medium
10/29/2020Wells Fargo & CompanyBoost TargetOverweight$255.00 ➝ $265.00Low
10/29/2020BTIG ResearchBoost TargetBuy$233.00 ➝ $259.00High
9/29/2020BTIG ResearchInitiated CoverageBuy$233.00Low
9/8/2020Bank of AmericaDowngradeBuy ➝ NeutralMedium
8/4/2020Wells Fargo & CompanyBoost TargetOverweight$205.00 ➝ $255.00Medium
8/4/2020CitigroupBoost TargetBuy$214.00 ➝ $264.00Medium
5/8/2020JPMorgan Chase & Co.Boost TargetOverweight$175.00 ➝ $200.00Low
5/8/2020CitigroupBoost TargetBuy$192.00 ➝ $214.00High
3/30/2020Wells Fargo & CompanyLower TargetOverweight$195.00 ➝ $180.00Medium
3/27/2020CitigroupLower TargetBuy$200.00 ➝ $192.00Low
3/4/2020CitigroupInitiated CoverageBuy$200.00Low
12/4/2019JPMorgan Chase & Co.Boost TargetOverweight$185.00 ➝ $200.00Medium
12/2/2019Royal Bank of CanadaReiterated RatingOutperform$192.00Low
8/7/2019Royal Bank of CanadaSet TargetBuy$174.00Low
8/1/2019Wells Fargo & CompanyBoost TargetOutperform$180.00 ➝ $185.00Low
6/13/2019Bank of AmericaBoost TargetBuy$150.00 ➝ $180.00Low
5/30/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$140.00 ➝ $170.00High
5/21/2019William BlairInitiated CoverageOutperformMedium
4/17/2019HC WainwrightReiterated RatingBuyHigh
11/6/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$150.00 ➝ $152.00High
10/29/2018Bank of AmericaReiterated RatingBuy ➝ Buy$36.00Low
10/8/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$174.00Low
8/9/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$140.00 ➝ $150.00Medium
5/31/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$150.00 ➝ $180.00Medium
5/9/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$115.00 ➝ $140.00High
4/4/2018The Goldman Sachs GroupInitiated CoverageBuy$145.00High
3/13/2018Wells Fargo & CompanyBoost TargetReduce ➝ Outperform$138.00Medium
2/28/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$110.00 ➝ $115.00Low
2/28/2018Wells Fargo & CompanyBoost TargetOutperform ➝ Outperform$120.00 ➝ $125.00High
2/21/2018William BlairInitiated CoverageOutperform ➝ OutperformLow
1/2/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
12/12/2017BMO Capital MarketsDowngradeOutperform ➝ Market Perform$117.00 ➝ $110.00High
11/8/2017BMO Capital MarketsBoost TargetOutperform$96.00 ➝ $117.00N/A
10/13/2017BMO Capital MarketsReiterated RatingBuy$96.00N/A
(Data available from 9/30/2017 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/4/2022
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/3/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/3/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/2/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/2/2022
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/1/2022
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/31/2022
  • 6 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/30/2022

Current Sentiment

  • 6 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Penumbra logo
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $189.60
Low: $189.39
High: $198.65

50 Day Range

MA: $170.69
Low: $129.38
High: $205.88

52 Week Range

Now: $189.60
Low: $114.86
High: $290.36

Volume

262,757 shs

Average Volume

310,289 shs

Market Capitalization

$7.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Penumbra?

The following Wall Street research analysts have issued research reports on Penumbra in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Needham & Company LLC, Royal Bank of Canada, StockNews.com, TheStreet, Truist Financial Co., Wells Fargo & Company, and William Blair.
View the latest analyst ratings for PEN.

What is the current price target for Penumbra?

10 Wall Street analysts have set twelve-month price targets for Penumbra in the last year. Their average twelve-month price target is $228.90, suggesting a possible upside of 20.7%. JPMorgan Chase & Co. has the highest price target set, predicting PEN will reach $300.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $163.00 for Penumbra in the next year.
View the latest price targets for PEN.

What is the current consensus analyst rating for Penumbra?

Penumbra currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PEN will outperform the market and that investors should add to their positions of Penumbra.
View the latest ratings for PEN.

What other companies compete with Penumbra?

How do I contact Penumbra's investor relations team?

Penumbra's physical mailing address is One Penumbra Place, Alameda CA, 94502. The company's listed phone number is (510) 748-3200 and its investor relations email address is [email protected] The official website for Penumbra is www.penumbrainc.com. Learn More about contacing Penumbra investor relations.